| DCE-016 |
Chenodeoxycholic acid |
>98%,Standard References |
|
| DC11547 |
LY-2562175
Featured
|
LY2562175 is a potent and selective FXR agonist, with an EC50 of 193 nM. |
|
| DC10868 |
Cilofexor
Featured
|
Cilofexor (GS-9674, GS9674) is novel specific, non-steroidal farnesoid X receptor (FXR) agonist that reduces liver fibrosis and ameliorates portal hypertension in rat NASH models. |
|
| DC8069 |
Fexaramate
Featured
|
Fexaramate is a potent, selective farnesoid X receptor agonist. |
|
| DC8085 |
Fexaramine
Featured
|
Fexaramine is a potent, selective FXR activator. |
|
| DC8070 |
Fexarene
Featured
|
Fexarene is a potent, selective farnesoid X receptor agonist. |
|
| DC8071 |
Fexarine
Featured
|
Fexarine is a potent, selective farnesoid X receptor agonist. |
|
| DC7566 |
GW-4064
Featured
|
GW 4064 is a selective, non-steroidal farnesoid X receptor (FXR) agonist (EC50 = 15 nM). |
|
| DC7430 |
Obeticholic acid (INT-747)
Featured
|
INT-747(Obeticholic acid; 6-ECDCA) is a potent and selective FXR agonist(EC50=99 nM) endowed with anticholestatic activity. |
|
| DC10470 |
SB756050
Featured
|
SB-756050 is a Farnesoid X receptor (FXR) (NR1H4) agonist. |
|
| DC10737 |
Tropifexor (LJN452)
Featured
|
Tropifexor (LJN452) is a highly potent non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH). |
|
| DC7040 |
WAY-362450 (XL335; Turofexorate isopropyl)
Featured
|
WAY-362450 (XL335; Turofexorate isopropyl) is a highly potent, selective, and orally active farnesoid X receptor (FXR) agonist with an EC50 of 4 nM.WAY-362450 is useful for dyslipidemia. |
|
| DC28475 |
NR1H4 activator 1 |
NR1H4 activator 1 is a potent and selective Famesoid X Receptor (FXR) agonist, extracted from patent WO2018152171A1, example 4. NR1H4 activator 1 shows strong FXR agonistic potency with a EC50 value of 1 nM in a Human FXR (NR1H4) Assay. NR1H4 activator 1 has the potential for treatment of gastrointestinal disease. |
|
| DC28850 |
Tauro-Obeticholic acid |
Tauro-Obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is an orally bioavailable farnesoid-X receptor (FXR) agonist. |
|
| DC28851 |
Glyco-Obeticholic acid |
Glyco-obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is a farnesoid X receptor (FXR) agonist. |
|
| DC46688 |
Sevelamer-(d5)n hydrochloride |
Sevelamer-(d5)n hydrochloride is the deuterium labeled Sevelamer hydrochloride. Sevelamer hydrochloride is a phosphate binding drug used to treat hyperphosphatemia in patients with chronic kidney disease; consists of polyallylamine that is crosslinked with epichlorohydrin. |
|
| DC47987 |
FXR/TGR5 agonist 1 |
FXR/TGR5 agonist 1 has agonist action on FXR and TGR5, and can be used for the treatment of fatty liver disease. |
|
| DC50221 |
NDB |
NDB is a selective human FXRα (hFXRα) antagonist that is effective in modulating transcription of FXRα downstream genes. NDB can be used in anti-diabetes research. |
|
| DC50222 |
BMS-986318 |
BMS-986318 is a potent nonbile acid FXR agonist with EC50s of 53 and 350 nM in the FXR Gal4 and SRC-1 recruitment assays, respectively. BMS-986318 has a suitable ADME profile, and demonstrates efficacy in the mouse bile duct ligation model of liver cholestasis and fibrosis.BMS-986318 can be used for the research of nonalcoholic steatohepatitis. |
|
| DC50223 |
Chenodeoxycholic acid-d5 |
Chenodeoxycholic acid-d5 (CDCA-d5) is the deuterium labeled Chenodeoxycholic Acid. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism. |
|
| DC50224 |
Chenodeoxycholic acid-13C |
Chenodeoxycholic acid-13C (CDCA-13C) is the 13C-labeled Chenodeoxycholic Acid. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism. |
|
| DC70074 |
GSK-2324 |
GSK-2324 (GSK2324) is a potent, selective, full FXR agonist with EC50 of 120 nM in FRET assay. |
|
| DC71956 |
BMS-986339
Featured
|
BMS-986339 is an orally active, potent FXR agonist. BMS-986339 forms H-bond with His298 and ASN287 residues. |
|
| DC71957 |
Omesdafexor |
Omesdafexor is a FXR agonist. Omesdafexor can be used in the research of liver disease or a metabolic inflammation-mediated disease. |
|
| DC73829 |
HPG1860 |
HPG1860 is a potent, selective, nonbile acid full FXR agonist with EC50 of 5 nM and 18 nM in FR-FRET and luciferase assays, respectively. |
|
| DC73830 |
ID166 |
ID119031166 (ID166) is a novel potent, selective FXR agonist with EC50 of 3 nM and 5 nM in TR-FRET FXR co-activator assay and FXR reporter assay, respectively. |
|
| DC73831 |
MET409 |
MET409 (MET-409) is a potent, selective farnesoid X receptor (FXR) agonist with EC50 of 16 nM (human FXR). |
|
| DC73832 |
PDL103 |
PDL103 is a potent, dual FXR/GPBAR1 antagonist with IC50 of 10 and 19 uM, respectively. |
|
DC Chemicals' products qualify for U.S. tariff exemptions. We guarantee no price increases due to customs duties and maintain stable supply, continuing to deliver reliable research solutions to our American clients.
